Aflibercept
- Generic Name
- Aflibercept
- Brand Names
- Eylea, Zaltrap, Yesafili
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 862111-32-8
- Unique Ingredient Identifier
- 15C2VL427D
- Background
Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It contains approximately 15%...
- Indication
The opthalmic agent is used for the treatment of neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and retinopathy of prematurity (ROP).
...
- Associated Conditions
- Branch Retinal Vein Occlusion With Macular Edema, Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Macular Edema With Central Retinal Vein Occlusions, Metastatic Colorectal Cancer (CRC), Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD), Retinopathy of Prematurity (ROP)
- Associated Therapies
- -
Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study)
- First Posted Date
- 2016-06-02
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- Pusan National University Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT02788877
- Locations
- 🇰🇷
Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of
🇰🇷Pusan National University Hospital, Busan, Korea, Republic of
🇰🇷Busan Paik Hospital, Busan, Korea, Republic of
PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept
- First Posted Date
- 2016-02-12
- Last Posted Date
- 2021-01-28
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 90
- Registration Number
- NCT02681783
- Locations
- 🇨🇦
Sunnybrook Research Institute, Toronto, Ontario, Canada
Aflibercept in Recurrent or Persistent CNV
- Conditions
- Interventions
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 80
- Registration Number
- NCT02669953
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study
- First Posted Date
- 2016-01-22
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Moorfields Eye Hospital NHS Foundation Trust
- Target Recruit Count
- 30
- Registration Number
- NCT02661711
- Locations
- 🇬🇧
Moorfields Eye Hospital, London, United Kingdom
Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2016-01-06
- Lead Sponsor
- Instituto de Olhos de Goiania
- Target Recruit Count
- 20
- Registration Number
- NCT02646670
Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis
- First Posted Date
- 2015-12-29
- Last Posted Date
- 2015-12-29
- Lead Sponsor
- Instituto de Olhos de Goiania
- Target Recruit Count
- 2
- Registration Number
- NCT02641457
- Locations
- 🇧🇷
Instituto de Olhos de Goiania, Goiania, GO, Brazil
Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 48
- Registration Number
- NCT02633852
Evaluation of Treatment of High riSk proLiferative Diabetic retinopathY With Intravitreal Aflibercept injectioN
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2015-12-15
- Lead Sponsor
- Valley Retina Institute
- Target Recruit Count
- 30
- Registration Number
- NCT02630277
Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment
- Conditions
- Interventions
- First Posted Date
- 2015-12-08
- Last Posted Date
- 2019-02-22
- Lead Sponsor
- Hellenic Oncology Research Group
- Target Recruit Count
- 31
- Registration Number
- NCT02624726
- Locations
- 🇬🇷
Anticanscer Hospital of Athens "Agios Savvas", Athens, Greece
🇬🇷University Hospital of Patras-Rio, Río, Greece
🇬🇷General Hospital of Athens "Aretaieio", Athens, Greece
Short-term Efficacy of Intravitreal Afilibercept Depending on Subtypes of Polypoidal Choroidal Vasculopathy: Polypoidal Choroidal Neovascularization or Idiopathic Choroidal Vasculopathy
- First Posted Date
- 2015-11-05
- Last Posted Date
- 2016-08-18
- Lead Sponsor
- Yeungnam University College of Medicine
- Target Recruit Count
- 29
- Registration Number
- NCT02597855
- Locations
- 🇰🇷
Yeungnam University College of Medicine, Daegu, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.